Pediatric Bladder Treatment Market Growth, Demand, Key Drivers, Forecast To 2033

The pediatric bladder treatment market size has grown strongly in recent years. It will grow from $3.36 billion in 2023 to $3.54 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to prevalence of pediatric bladder conditions, growing awareness of pediatric bladder conditions, increasing access to healthcare for children, rising disposable incomes.

The pediatric bladder treatment market size is expected to see steady growth in the next few years. It will grow to $4.23 billion in 2028 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to aging population, rising prevalence of chronic diseases in children, increasing access to healthcare, demand for personalized medicine in the treatment. Major trends in the forecast period include adoption of new and innovative pediatric bladder treatments, digital health technologies, early intervention and prevention, non-invasive treatments.

Market Overview -
Pediatric bladder disorders refer to a spectrum of medical issues affecting the urinary bladder in children, encompassing conditions that impact bladder function, control and structure. Pediatric bladder treatment refers to managing and treating bladder dysfunction, where treatment options vary depending on age, overall health, medical history, bladder symptoms and the cause of the nerve damage or neurologic condition.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12943&type=smp

Rising Prevalence Of Pediatric Bladder Disorders Fuels Growth In The Pediatric Bladder Treatment Market
The increasing prevalence of pediatric bladder disorders is expected to propel the growth of the pediatric bladder treatment market going forward. Pediatric bladder disorders refer to various medical conditions that impact the normal functioning of the urinary bladder in children. Conditions such as spina bifida and neurological disorders contribute to urinary problems in children, necessitating effective treatments. For instance, in March 2023, according to a journal published by the Multidisciplinary Digital Publishing Institute (MDPI), a Switzerland-based publishing company, in a study involving 1,065 pediatric patients with neurogenic bladder (NGB), 38.9% of patients had spina bifida. The primary complication observed was lower urinary tract infection (18.1%), particularly prevalent among patients with open spina bifida (54.1%). Moreover, over a 12-month follow-up, common prevalent complications included lower urinary tract infections (18.1%), urinary incontinence (8.0%) and hydronephrosis (5.6%), with 7.9% of patients facing four or more recurring lower urinary tract infections. Therefore, the increasing prevalence of pediatric bladder disorders will drive the growth of the pediatric bladder treatment market.

Competitive Landscape -
Major players in the pediatric bladder treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Medtronic PLC, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Mylan N.V., Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cook Medical Inc., Ipsen Pharma, Aurobindo Pharma Ltd., Endo International PLC, Coloplast AIS, Endo International PLC, Apotex Inc., Amneal Pharmaceuticals LLC., Orion Corporation, Taro Pharmaceuticals, Laborie Medical Technologies Corp., Salix Pharmaceuticals, TherapeuticsMD Inc., UroGen Pharma, Palette Life Sciences, Sumitovant Biopharma.

Innovation In Precision Treatment For Unique Medical Needs
Major companies operating in the pediatric bladder treatment market are developing targeted therapies to address specific medical conditions in the pediatric population and provide tailored solutions for unique patient demographics and medical needs. Targeted therapies in pediatric bladder treatment refer to the specialized and precise medical interventions designed to effectively address children with bladder disorders' unique challenges and requirements. For instance, in March 2021, Astellas Pharma Inc., a Japan-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron extended-release oral suspension) for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older. Neurogenic detrusor overactivity (NDO) is a form of bladder dysfunction stemming from nerve damage that manifests through involuntary bladder contractions, resulting in symptoms such as frequent urination, an urgent need to urinate and urinary incontinence. Myrbetriq tablets (Mirabegron extended-release tablets) are presently accessible in the U.S. market.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/pediatric-bladder-treatment-global-market-report

Key Segments -
The pediatric bladder treatment market covered in this report is segmented -
1) By Type: Diurnal Incontinence; Enuresis; Other Types
2) By Treatment: Urotherapy; Medication; Surgical Reconstruction; Other Treatments
3) By Route of Administration: Oral; Parenteral; Other Route of Administrations
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

"Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

"Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps"

This release was published on openPR.